

Co-expression of the proprotein-processing endoprotease furin and its substrate transforming growth factor β 1 and the differentiation of rat hepatocytes

Hideki Hoshino, Yoshitaka Konda, Toshiyuki Takeuchi*

Department of Molecular Medicine, Institute for Molecular and Cellular Regulation, Gunma University, Showa-machi, Maebashi 371, Japan

Received 9 October 1997

Abstract Furin, a member of the yeast Kex2 endoprotease family, converts a number of proproteins to their active forms. The liver produces a number of proproteins having a furin-cleavable site; thus, furin may be involved in growth and differentiation both in the partially hepatectomized liver and in primary cultured hepatocytes. Furin mRNA levels are elevated in tissues regenerated from partially hepatectomized rat liver. In primary culture of rat hepatocytes, furin expression increases gradually with time, and its expression is greatly enhanced by transforming growth factor β 1, whose processing from the precursor requires cleavage by furin. Thus, we suggest that the regeneration and differentiation of hepatocytes is dependent upon the co-elevation of furin and transforming growth factor β 1 mRNAs.

© 1997 Federation of European Biochemical Societies.

Key words: Furin; Partial hepatectomy; Hepatocyte; Transforming growth factor β

1. Introduction

Furin, a proprotein-processing enzyme, is a member of the yeast Kex2 family of endoproteases that contain a subtilisin-like serine-protease domain as an active site [1,2]. This enzyme is distributed more or less in virtually all tissues, and high expression is observed in the normal liver [3]. Furin cleaves the carboxy-terminus of the unique consensus sequence $-\text{Arg}^{-4}\text{-X}^{-3}\text{-Lys/Arg}^{-2}\text{-Arg}^{-1}$ [RX(K/R)R]. The most essential residues of this sequence are the Args at the -1 and -4 positions. However, Arg^{-6} can replace Arg^{-4} , although this renders the cleavage of RXXX(K/R)R by furin less efficient [4]; thus, for cleavage to occur properly, more basic amino acids are required ahead of the general cleavage site of most propeptide hormones, $-(\text{Lys/Arg})^{-2}\text{-Arg}^{-1}$ [2]. A number of proproteins are known to contain this furin-cleavable motif [1]: growth factor precursors including platelet-derived growth factor (PDGF), transforming growth factor β (TGF β), activin A, and insulin-like growth factor-1 (IGF-1); some growth factor proreceptors such as insulin receptor, IGF-1 receptor, and hepatocyte growth factor (HGF) receptor (oncoprotein *MET*); matrix metalloproteinases (MMP) such as stromelysin-3 and membrane-type MMP-1; adhesion molecules such as the cadherin family and integrins α 3 and α 6; and many plasma proteins including albumin, coagulation factors VII, IX, and X, and von Willebrand factor, and plasminogen activator-1. The liver, including mesenchymal and

non-mesenchymal cells, contains these proproteins as listed in Table 1.

Previously, we found that furin is highly expressed during the growth state of many cell types. When furin is highly expressed in well-differentiated pancreatic β cell line MIN6 cells, the β cell-specific differentiated characteristics such as insulin content, expression of prohormone convertases PC2 and PC3, and glucose-regulated insulin secretion, diminish [5]. A β cell line, such as MIN6 and β HC9, with a higher level of insulin content and secretory granules expresses a low level of furin, and exhibits slower cell growth; whereas a β cell line with less-differentiated characteristics, such as β TC3 and RINm5F, expresses a high level of furin and grows much faster than differentiated β cell lines [5,6]. Furin is highly expressed in whole rat islets during the perinatal period, when islet cell replication is most extensive, expression then decreases as development continues toward the adult stage [7]. We also found in the adult rat gastric gland furin-positive cells layered along the proliferative cell zone. By using a gastric surface mucosal cell line, GSM06, we demonstrated that when furin expression is suppressed by its antisense oligonucleotide, cell growth is retarded and expression of the differentiated characteristics, such as the appearance of periodic acid-Schiff-positive materials, is enhanced [8]. In cardiac myocytes, furin was strongly immunostained when the cells underwent hypertrophic growth by stretching [9]. When we infarcted the hearts of rats by ligation of the left descending coronary artery, we found that furin was highly expressed along the cells adjacent to the infarcted area [10]. Thus, we propose that furin is expressed when dividing cells undergo proliferation and non-dividing cells experience hypertrophic growth.

The liver has an enormous capacity to regenerate following either partial hepatectomy or massive liver damage by severe hepatitis [11,12]. During its regenerative growth, a number of growth factors and growth-related proteins are expressed in a cascade fashion. After regeneration, the liver produces a massive amount of plasma proteins to maintain homeostasis. As listed in Table 1, many proproteins produced in the liver contain a furin-specific cleavage site. However, some growth factors and proreceptors, such as PDGF, IGF-1, and c-Met, induce hepatocytic growth, whereas others, such as TGF β and activin A, induce cell differentiation. As for plasma proteins, some proproteins including complements are produced in the acute-phase response to injury, while others such as albumin are produced primarily from the normal-state liver. However, we do not yet know whether furin expressed for the conversion of proproteins derives from the growing or the differentiated state of the hepatocytes. The present study demonstrates changes in the expression of furin and its substrate

*Corresponding author. Fax: (81) (272) 20-8896.
E-mail: ttakeuchi@news.sb.gunma-u.ac.jp

TGF β after a partial hepatectomy and during the primary culturing of the hepatocytes.

2. Materials and methods

2.1. Materials

Recombinant TGF β 1 was obtained from King Jyozo (Himeji, Japan), EGF from Collaborative Biomedical Products (Bedford, MA, USA). Male Wistar rats (150–200 g) were purchased from Imai Experimental Animal Farm (Saitama, Japan).

2.2. Surgical procedures

Rats were maintained under controlled light (7:00 to 19:00 h) with food and water provided ad libitum. Partial (70%) hepatectomy was performed under anesthesia with diethyl ether, as described previously [13]. After opening the peritoneal cavity, the left lateral and left median lobes were excised from the liver. Control operations were performed using an identical procedure without excision of any liver tissue. At an indicated time after the operation, the rats were killed and their livers were removed for RNA isolation.

2.3. Hepatocyte isolation and culture

Hepatocytes were prepared by perfusion of the liver with collagenase [14]. Cells were plated close to confluence ($6\text{--}7 \times 10^4/\text{cm}^2$) on a 90-mm collagen-coated dish in Williams' E medium, containing 5% fetal bovine serum, 10 nM insulin, 1 nM dexamethasone, streptomycin and penicillin. After 3 h, the cells were washed with phosphate-buffered saline, then incubated in fresh, serum-free Williams' E medium, containing 0.1% bovine serum albumin (BSA) with EGF (10 ng/ml) or TGF β 1 (usually at 100 pM; in other cases at an indicated concentration). Culture media were replaced every 24 h.

2.4. RNA extraction and hybridization

Total RNA was extracted from primary cultured hepatocytes or

partially hepatectomized liver with TRIzol reagent (Life Technologies, Grand Island, NY, USA). For Northern blot analysis, total RNA (10 μ g) was heat-denatured and electrophoresed on a 1% agarose gel, then transferred to a nylon membrane (Hybond-N, Amersham Japan, Tokyo, Japan). Hybridization was performed in a solution consisting of 5 \times SSPE (20 \times SSPE = 3.0 M NaCl, 200 mM NaH $_2$ PO $_4$, 20 mM EDTA, pH 7.4), 10 \times Denhardt's reagent (0.2% Ficoll, 0.2% polyvinylpyrrolidone, 0.2% BSA), 50% formamide, 1.4% sodium dodecyl sulfate (SDS), and 0.1 mg/ml salmon sperm DNA with either a mouse furin cDNA probe (a 924-bp fragment cut with *Bam*HI [5]) or a rat TGF β 1 cDNA probe (a 490-bp fragment cut with *Eco*RI and *Bgl*II [15]), labeled with [α - 32 P]dCTP, using a *red*i prime random primer labeling kit (Amersham Japan, Tokyo). After washing, the membrane was exposed to X-ray film with an intensifying screen at -80°C .

3. Results

3.1. Furin expression after partial hepatectomy

Total RNA derived from the remaining liver after the partial hepatectomy or after the control operation was subjected to Northern blot analysis for furin expression. After a control operation, furin mRNA levels remained relatively constant up to 168 h (7 days) (Fig. 1A); however, after partial hepatectomy, furin expression decreased at 3–6 h, returned to control levels at 12–18 h, then gradually increased from 24–168 h (Fig. 1B). This decrease of furin mRNA was confirmed by a total of eight experiments. Furthermore, 18S and 28S ribosomal RNAs were equally stained with ethidium bromide at each point (Fig. 1C). Because the proliferation of hepatocytes is maximal 24 h after partial hepatectomy, 3–6-h points are in the middle of the G1 phase of the cell cycle [11]. At this phase,

Table 1
A list of liver-produced proproteins with a furin-cleavable site

Proprotein	Propeptide										Bioactive peptide
	−6					−4					+1
Growth factors											
PDGF-A	-K	R	P	L	P	I	R	R	K	R	SIE-
PDGF-B	-E	L	E	S	L	A	R	G	R	R	SLG-
IGF-1	-A	P	L	K	P	A	K	S	A	R	SVR-
TGF- β	-Q	H	L	Q	S	S	R	H	R	R	ALD-
Activin A	-E	D	H	P	H	R	R	R	R	R	GLE-
PTHrP	-V	E	G	S	L	R	R	L	K	R	AVS-
Plasma proteins											
Albumin					R	G	V	F	R	R	DAH-
Factor VII	-A	H	G	V	L	H	R	R	R	R	ANA-
Factor IX	-A	N	K	I	L	N	R	P	K	R	YNS-
Factor X	-G	K	Q	T	L	E	R	R	K	R	SVA-
von Willebrand factor	-S	S	P	L	S	H	R	S	K	R	SLS-
Tissue-type plasminogen activator	-I	H	A	R	F	R	R	G	A	R	SVQ-
Prothrombin	-A	R	S	L	L	Q	R	V	R	R	ANT-
Protein C	-M	E	K	K	R	S	H	L	K	R	DTE-
Matrix metalloproteinases (MMP)											
Stromelysin-3	-G	L	S	A	R	N	R	Q	K	R	FVL-
Membrane-type MMP-1	-E	I	K	A	N	V	R	R	K	R	YAI-
Adhesion molecules											
E-cadherin	-S	S	P	G	L	R	R	Q	K	R	DWV-
Integrin α 3 H-L chain	-R	P	S	S	P	Q	R	R	R	R	QLD-
Integrin α 6 H-L chain	-T	E	S	H	N	S	R	K	K	R	EIT-
Complements											
C $_3$ β - α chains	-C	P	Q	P	A	A	R	R	R	R	SVQ-
C $_4$ β - α chains	-P	K	E	K	T	T	R	K	K	R	NVN-
C $_4$ α - γ chains	-F	E	G	R	R	N	R	R	R	R	EAP-
C $_5$ β - α chains	-P	C	K	E	I	L	R	P	R	R	TLQ-
Pro-receptors											
Insulin receptor α - β chains	-F	V	P	R	P	S	R	K	R	R	SLG-
HGF receptor (c-Met) α - β chains	-C	I	L	T	E	K	R	K	K	R	STK-

A furin-cleavable consensus sequence is Arg $^{-4}$ -X-(Lys/Arg) $^{-2}$ -Arg $^{-1}$. Albumin does not possess Arg $^{-4}$, but instead possess Arg $^{-6}$. Basic residues from -1 to -6 positions are written in bold.




Fig. 1. Northern blot analyses of furin mRNAs after partial hepatectomy. A: Furin mRNAs from control-operated livers. B: Furin mRNAs from the partially hepatectomized liver. Time (h) after the operation is indicated at the top of the panel. The arrowhead indicates 28S rRNA. The size of furin mRNA is approximately 4.5 kb. C: 18S and 28S rRNA bands stained with ethidium bromide.

furin was under-expressed in the partially resected liver. Because furin mRNA levels became elevated toward the 168-h point, furin may be involved in the production of proproteins related to cell differentiation.

3.2. Furin expression in primary cultured hepatocytes

The gene expression pattern of a primary culture of hepatocytes in the presence of a cocktail of insulin, glucocorticoid, and EGF roughly simulates that of partially resected liver [16]. In the presence of 10 ng/ml EGF, hepatocytes initially grow, then display differentiated features. Furin mRNA was elevated approaching the 72-h point post culture (Fig. 2A). Furin is known to convert pro-TGF β to its active form [17], which then induces a differentiated state of hepatocytes. When TGF β (final 100 pM) was further added to the culture medium, furin mRNA levels were markedly elevated, even at the 24-h point, increasing up to 72 h post culture (Fig. 2B). This furin expression was TGF β 1 dose-dependent up to 300 pM (Fig. 2C), and the effect was significant at concentrations




Fig. 2. Northern blot analyses of furin mRNAs in primary cultured hepatocytes. A: Furin mRNAs after the addition of 10 ng/ml EGF to the culture. B: Furin mRNAs after the addition of 10 ng/ml EGF and 0.1 nM TGF β 1 to the culture. Time (h) after the addition of EGF or TGF β 1 is indicated at the top of the panel. C: Expression of furin mRNAs after the addition of increasing amounts of TGF β 1 for 72 h. TGF β 1 dosage is indicated at the top of the panel. The arrowhead indicates 28S rRNA.




Fig. 3. Northern blot analyses of TGF β 1 mRNAs after partial hepatectomy. A: TGF β 1 mRNAs from control-operated livers. B: TGF β 1 mRNAs from the partially hepatectomized liver. Time (h) after the operation is indicated at the top of the panel. The arrowhead indicates 18S rRNA. The size of TGF β 1 mRNA is approximately 2.5 kb.

greater than 100 pM TGF β 1. Thus, TGF β is a strong inducer of furin in hepatocytes.

3.3. TGF β 1 expression after partial hepatectomy

When furin is expressed, its substrate proproteins may be co-expressed. After partial hepatectomy, furin expression increased up to the 168-h point, as already shown in Fig. 1B; likewise, TGF β 1 mRNA expression increased toward the 168-h point in partially hepatectomized rat livers (Fig. 3B), but stayed at the same low level in the control rat livers (Fig. 3A). Thus, although the increase of furin mRNA occurred earlier than did that of TGF β 1 mRNA, both furin and TGF β mRNAs co-elevated after partial hepatectomy.

3.4. TGF β 1 expression in primary cultured hepatocytes

In the primary culturing of hepatocytes using EGF, TGF β 1 expression was only faintly visible at the 72-h point (Fig. 4A). Adding TGF β 1 to the culture resulted in increased levels of TGF β 1 mRNA expression at the 72-h point (Fig. 4B), similar to the furin mRNA expression levels (Fig. 2B). Also, TGF β 1 expression was TGF β 1 dose-dependent up to 300 pM (Fig. 4C), and the TGF β 1 effect was noted above 100 pM TGF β 1. Thus, TGF β 1 and furin mRNAs were co-elevated in partially hepatectomized liver as well as in primary cultured hepatocytes.

4. Discussion

This study demonstrated that furin is highly expressed with the differentiation of hepatocytes, and its expression is greatly enhanced by the same TGF β 1 that is known to inhibit the growth of hepatocytes and to induce their differentiation [11,12]. This expression mode of furin is contrary to our previous findings which detected expression in the growing state of pancreatic β cells, gastric surface mucous cells, and cardiac myocytes, as described in Section 1 [5–10].

The liver produces a number of proproteins with furin-cleavable sites, as listed in Table 1 [1]. Some of these, such as PDGF, IGF1 and c-Met, are involved in the liver regeneration. Because furin expression was high in normal and regenerated liver and low shortly after partial hepatectomy (Fig. 1), these proproteins may be cleaved by other Kex2 family endoproteases, such as PACE4 [18]. Several bioactive proteins are known to induce hepatocyte differentiation in an autocrine/paracrine fashion. The most well-known proprotein is TGF β , which inhibits the growth and induces the differentiation of hepatocytes [11,12,19]. TGF β is produced as a latent




Fig. 4. Northern blot analyses of TGF β 1 mRNAs in primary cultured hepatocytes. A: TGF β 1 mRNAs after the addition of 10 ng/ml EGF to the culture. B: TGF β 1 mRNAs after the addition of 10 ng/ml EGF and 0.1 nM TGF β 1 to the culture. Time (h) after the addition of EGF or TGF β 1 is indicated at the top of the panel. C: Expression of TGF β 1 mRNAs after the addition of increasing amounts of TGF β 1 over 72 h. TGF β 1 dosage is indicated at the top of the panel. The arrowhead indicates 18S rRNAs.

form composed of three components: a 25-kDa TGF β dimer, a cleaved propeptide dimer non-covalently bound to TGF β , and a latent TGF β -binding protein (LTBP). The latent form of TGF β requires two processing reactions for maturation: first, cleavage of TGF β propeptide precursor by furin [17], and second, removal of LTBP possibly by plasmin [20]. Thus, furin is required for the activation of pro-TGF β . Furthermore, TGF β 1 is known to upregulate its own expression [21]. Previously, we suggested that whenever furin is expressed, its substrate proproteins will be co-expressed in the same cell; brain natriuretic peptide is one such proprotein that is co-expressed with furin in the hypertrophic cardiac myocytes by stretching [9,10]. TGF β 1 is reported to induce the expression of furin in cultured rat synovial cells as early as 3–48 h after the addition of TGF β 1 [22]. We also confirmed that TGF β 1 induces the expression of both furin and TGF β 1 in partially hepatectomized liver and also in primary cultured hepatocytes.

In the liver, most of the TGF β 1 is produced by endothelial cells and Kupffer cells, a smaller amount by fat-storing cells (also called lipocytes and Ito cells), and a much smaller amount by hepatocytes [23]. In our experiments, TGF β 1 as well as furin expression was faintly visible in cultured hepatocytes unless TGF β 1 had been added to the culture. Since the normal liver and regenerated liver express a high level of furin, we need to examine whether furin distribution is similar to TGF β 1 distribution in the liver cell types. Although TGF β 1 production was not high, hepatocytes are known to continue producing TGF β 1 over 72 h compared with an hourly rise of TGF β 1 in the other three liver cell types in primary culture [23]. In hepatocytes, TGF β induced expression of furin and additional levels of TGF β . Thus, induced

furin may activate not only pro-TGF β but also other proproteins, such as the plasma proteins, which are instrumental for maintaining homeostasis.

Acknowledgements: This work was supported by grants-in-aid from the Ministry of Education, Science, Culture and Sports of Japan. We are grateful to Ms. Reiko Uchida for her secretarial assistance.

References

- [1] Nakayama, K. (1997) *Biochem. J.* 323, 625–635.
- [2] Smeeckens, S.P. (1993) *Biotechnology* 11, 182–186.
- [3] Schalken, J.A., Roebroek, A.J.M., Oomen, P.P.C.A., Wagenaar, S.S., Debruyne, F.M.J., Bloemers, H.P.J. and Van de Ven, W.J.M. (1987) *J. Clin. Invest.* 80, 1545–1549.
- [4] Liu, Y.C., Kawagishi, M., Mikayama, T., Inagaki, Y., Takeuchi, T. and Ohashi, H. (1993) *Proc. Natl. Acad. Sci. USA* 90, 8957–8961.
- [5] Kayo, T., Sawada, Y., Suzuki, Y., Suda, M., Tanaka, S., Konda, Y., Miyazaki, J. and Takeuchi, Y. (1996) *J. Biol. Chem.* 271, 10731–10737.
- [6] Kayo, T., Sawada, Y., Suda, M., Konda, Y., Izumi, T., Tanaka, S., Shibata, H. and Takeuchi, T. (1997) *Diabetes* 46, 1296–1304.
- [7] Kayo, T., Konda, Y., Tanaka, S., Takata, K., Koizumi, A. and Takeuchi, T. (1996) *Endocrinology* 137, 5126–5134.
- [8] Konda, Y., Yokota, H., Kayo, T., Horiuchi, T., Sugiyama, N., Tanaka, S., Takata, K. and Takeuchi, T. (1997) *J. Clin. Invest.* 99, 1842–1851.
- [9] Sawada, Y., Suda, M., Yokoyama, H., Kanda, T., Sakamaki, T., Tanaka, S., Nagai, R., Abe, S. and Takeuchi, T. (1997) *J. Biol. Chem.* 272, 20545–20554.
- [10] Sawada, Y., Inoue, M., Kanda, T., Sakamaki, T., Tanaka, S., Minamino, N., Nagai, R. and Takeuchi, T. (1997) *FEBS Lett.* 400, 177–182.
- [11] Mivhalopoulos, G.K. and DeFrances, M.C. (1997) *Science* 276, 60–66.
- [12] Haber, B.A., Mohn, K.L., Diamond, R.H. and Taub, R. (1993) *J. Biol. Chem.* 268, 1319–1326.
- [13] Kogure, K., Omata, W., Kanzaki, M., Zhang, Y., Yasuda, H., Mine, T. and Kojima, I. (1995) *Gastroenterology* 108, 1136–1142.
- [14] Yasuda, H., Mine, T., Shibata, H., Eto, Y., Hasegawa, Y., Takeuchi, T., Asano, S. and Kojima, I. (1993) *J. Clin. Invest.* 92, 1491–1496.
- [15] Tsuji, T., Okada, F., Yamaguchi, K. and Nakamura, T. (1990) *Proc. Natl. Acad. Sci. USA* 87, 8835–8839.
- [16] Francavilla, A., Staral, T.E., Van Thiel, D.H., Barone, M. and Polimeno, L. (1993) in: *Molecular and Cell Biology of the Liver*, pp. 309–346.
- [17] Dubois, C.M., Laprise, M., Blanchette, F., Gentry, L.E. and Ledue, R. (1995) *J. Biol. Chem.* 270, 10618–10624.
- [18] Kiefer, M.C., Tucker, J.E., Joh, R., Landsberg, K.E., Saltman, D. and Berr, P.J. (1991) *DNA Cell Biol.* 10, 757–769.
- [19] Massague, J. (1990) *Annu. Rev. Cell. Biol.* 6, 597–641.
- [20] Taipale, J., Miyazono, K., Heldin, C. and Keski-Oja, J. (1994) *J. Cell. Biol.* 124, 171–181.
- [21] Obberghen-Schilling, E.V., Roche, N.S., Flanders, K.C., Sporn, M.B. and Roberts, A.B. (1988) *J. Biol. Chem.* 263, 7741–7746.
- [22] Blanchette, F., Day, R., Dong, W., Laprise, M.-H. and Dubois, C.M. (1997) *J. Clin. Invest.* 99, 1974–1983.
- [23] Bissell, D.M., Wang, S., Jarnagin, W.R. and Joseph Roll, F. (1995) *J. Clin. Invest.* 96, 447–455.